Illumina's Q3 Revenues Rise 21 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its third-quarter revenues increased 21 percent year over year, as the firm beat Wall Street estimates on the top and bottom line.

The San Diego-based genetic analysis tools firm reported total revenues of $285.9 million, up from $235.5 million for Q3 2011 and above analysts' consensus estimate of $284.8 million. Its product revenues climbed to $262.4 million from $220.3 million, and its service and other revenue jumped to $23.5 million from $15.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.